A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma

Trial Profile

A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2015

At a glance

  • Drugs Cintredekin besudotox (Primary)
  • Indications Adrenocortical carcinoma; Liver cancer; Pancreatic cancer; Phaeochromocytoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors INSYS Pharma
  • Most Recent Events

    • 17 Nov 2014 Status changed from recruiting to discontinued according to the ClincalTrials.gov record.
    • 17 Nov 2014 Status changed from recruiting to discontinued according to the ClincalTrials.gov record.
    • 03 Sep 2014 As per NCt record, no. of tt. arms changed from 1 to 4; time points for end points are changed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top